Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

被引：0
|
作者：
Fischer, S. [1 ]
Klenske, E. [1 ]
Schmitt, H. [1 ]
Vitali, F. [1 ]
Hirschmann, S. [1 ]
Koch, F. [1 ]
Ramming, A. [2 ]
Zundler, S. [1 ]
Nagore, D. [3 ]
Uter, W. [4 ]
Neurath, M. F. [1 ]
Atreya, R. [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 3, Erlangen, Germany
[3] Progent Biopharma, Derio, Spain
[4] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S416 / S416
页数：1
相关论文
共 50 条
  • [1] SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis
    Macaluso, F. S.
    Cappello, M.
    Giuffrida, E.
    Fries, W.
    Centritto, A.
    Privitera, A. C.
    Inserra, G.
    Vassallo, R.
    Magnano, A.
    Vinci, E.
    Garufi, S.
    Ventimiglia, M.
    Renna, S.
    Orlando, R.
    Rizzuto, G.
    Cottone, M.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S490 - S490
  • [2] Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
    Fischer, Sarah
    Cohnen, Sarah
    Klenske, Entcho
    Schmitt, Heike
    Vitali, Francesco
    Hirschmann, Simon
    Ramming, Andreas
    Zundler, Sebastian
    Rath, Timo
    Krebs, Sabine
    Dorje, Frank
    Uter, Wolfgang
    Nagore, Daniel
    Meyer, Sebastian
    Neurath, Markus F.
    Atreya, Raja
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [3] SPOSIB SB2-A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2 (FLIXABI®): INTERIM ANALYSIS
    Macaluso, F. S.
    Cappello, M.
    Giuffrida, E.
    Fries, W.
    Centritto, A.
    Privitera, A. C.
    Inserra, G.
    Vassallo, R.
    Magnano, A.
    Vinci, E.
    Garufi, S.
    Ventimiglia, M.
    Renna, S.
    Orlando, R.
    Rizzuto, G.
    Cottone, M.
    Orlando, A.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E110 - E110
  • [4] Clinical outcomes of switching from originator to biosimilar infliximab in inflammatory bowel disease
    Lin, M. C-P
    Fauzi, M. N. B. M.
    Subramaniam, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 149 - 150
  • [5] Switching patients with inflammatory bowel disease from originator to biosimilar SB2 infliximab: A single-center Australian longitudinal study
    Llewelyn, J.
    Radford-Smith, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 123 - 123
  • [6] SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILAR SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO UNDERWENT A SWITCH FROM INFLIXIMAB BIOSIMILAR CT-P13
    Lovero, R.
    Losurdo, G.
    Biscaglia, G.
    Valvano, M. R.
    Biancofiore, A.
    Martino, G.
    Nardella, M.
    Andriulli, A.
    Principi, M.
    Bossa, F.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E227 - E227
  • [7] SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
    Macaluso, F. S.
    Fries, W.
    Viola, A.
    Centritto, A.
    Cappello, M.
    Giuffrida, E.
    Privitera, A. C.
    Piccillo, G.
    Magnano, A.
    Vinci, E.
    Vassallo, R.
    Trovatello, A.
    Belluardo, N.
    Giangreco, E.
    Camilleri, S.
    Garufi, S.
    Bertolami, C.
    Ventimiglia, M.
    Renna, S.
    Orlando, R.
    Rizzuto, G.
    Grova, M.
    Orlando, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S387 - S388
  • [8] The Safety of Switching From Originator Infliximab or Biosimilar CT-P13 to SB2 Among a Nationwide Cohort of Inflammatory Bowel Disease Patients
    Pernes, Tyler
    Patel, Manthankumar
    Khan, Nabeel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S405 - S405
  • [9] Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
    Lovero, Rosa
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Terracciano, Fulvia
    Biscaglia, Giuseppe
    Martino, Giuseppina
    Nardella, Marianna
    Di Leo, Alfredo
    Principi, Mariabeatrice
    Andriulli, Angelo
    Bossa, Fabrizio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 201 - 207
  • [10] Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
    Massimi, Davide
    Barberio, Brigida
    Bertani, Lorenzo
    Costa, Francesco
    Ferronato, Antonio
    Facchin, Sonia
    Cardin, Romilda
    Cingolani, Linda
    Casadei, Cesare
    D'Inca, Renata
    Zingone, Fabiana
    Savarino, Edoardo Vincenzo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
12345